


Engineered Neural Tissues (ENTs) for neurotoxicology testing and drug development

ENTs are premier quality engineered neuronal products and technologies that can be used for toxicology testing and for the development of neuroprotective drugs. We offer a platform of reproducible technologies consisting of targeted differentiation of pluripotent stem cells into neural tissues that have been developed and tested. Our technology, which is being developed by the team of Prof. Karl-Heinz Krause with laboratories at the University of Geneva, will ultimately replace animal models in that our platform is the only *in vitro* model that accurately mimics anatomical and physiological systems. In addition to being more humane and less costly compared to *in vivo* systems, our platform offers the advantage of offering real-time and robotic imaging of tissue response to potential toxins with simple and quantitative read-outs.

ENTs represents a unique high quality platform for testing neurotoxicity of chemicals and drugs in a relevant human target tissue.

Our offer:

- pluripotent stem cells for neurotoxicology testing and drug development
 - mouse and human
 - reporter genes for easy toxicology monitoring
 - 2D cell culture and 3D neural tissues
 - embryonic and induced pluripotent stem cells
 - disease models (eg. Glioblastoma and AD)
- flexible conditions
 - send frozen neural cells or tissues (cell pellet, multi-well plates)
 - perform testing in-house



Intellectual Property

We are developing a solid patent portfolio based on the methodology and molecules required to engineer neural tissue from pluripotent stem cells. Through our entity, Research Development Foundation, have filed several US and international patent applications.

For more information, please contact our business development unit:
Dr. Alexandra Richardson +41-76-342-7147 - arichardson@claytonbiotech.com